CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 173 filers reported holding CLOVIS ONCOLOGY INC in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $131,000 | -32.8% | 64,477 | -10.1% | 0.00% | – |
Q4 2021 | $195,000 | -35.6% | 71,751 | +5.3% | 0.00% | – |
Q3 2021 | $303,000 | -75.3% | 68,126 | -67.8% | 0.00% | -100.0% |
Q2 2021 | $1,227,000 | +126.4% | 211,464 | +174.4% | 0.00% | – |
Q1 2021 | $542,000 | +83.7% | 77,066 | +25.5% | 0.00% | – |
Q4 2020 | $295,000 | +13.0% | 61,423 | +37.1% | 0.00% | – |
Q3 2020 | $261,000 | -14.7% | 44,816 | -1.3% | 0.00% | – |
Q2 2020 | $306,000 | -86.0% | 45,408 | -86.8% | 0.00% | -100.0% |
Q1 2020 | $2,181,000 | +0.5% | 342,995 | +64.7% | 0.00% | +100.0% |
Q4 2019 | $2,170,000 | +26.0% | 208,311 | -52.5% | 0.00% | 0.0% |
Q3 2019 | $1,722,000 | -66.8% | 438,683 | +25.7% | 0.00% | -66.7% |
Q2 2019 | $5,186,000 | -14.3% | 348,867 | +43.0% | 0.00% | -25.0% |
Q1 2019 | $6,051,000 | -32.4% | 243,903 | -51.1% | 0.00% | -33.3% |
Q4 2018 | $8,947,000 | -51.8% | 498,291 | -21.1% | 0.01% | +20.0% |
Q3 2018 | $18,549,000 | -5.4% | 631,677 | +46.4% | 0.01% | -16.7% |
Q2 2018 | $19,615,000 | -24.1% | 431,451 | -11.9% | 0.01% | -50.0% |
Q1 2018 | $25,858,000 | +56.1% | 489,758 | +101.0% | 0.01% | +9.1% |
Q4 2017 | $16,565,000 | -10.1% | 243,628 | +8.9% | 0.01% | -15.4% |
Q3 2017 | $18,425,000 | -34.9% | 223,638 | -26.0% | 0.01% | -35.0% |
Q2 2017 | $28,296,000 | +86.0% | 302,233 | +26.5% | 0.02% | +81.8% |
Q1 2017 | $15,210,000 | +171.5% | 238,926 | +89.3% | 0.01% | +120.0% |
Q4 2016 | $5,603,000 | +10.5% | 126,195 | -10.3% | 0.01% | +25.0% |
Q3 2016 | $5,069,000 | -0.8% | 140,654 | -62.3% | 0.00% | 0.0% |
Q2 2016 | $5,111,000 | +26.4% | 372,673 | +77.0% | 0.00% | +33.3% |
Q1 2016 | $4,042,000 | -50.1% | 210,595 | -9.0% | 0.00% | -50.0% |
Q4 2015 | $8,097,000 | -57.4% | 231,385 | +11.9% | 0.01% | -60.0% |
Q3 2015 | $19,012,000 | +23.6% | 206,758 | +18.1% | 0.02% | +50.0% |
Q2 2015 | $15,384,000 | +155.6% | 175,071 | +115.8% | 0.01% | +150.0% |
Q1 2015 | $6,018,000 | +7.6% | 81,108 | -18.9% | 0.00% | +33.3% |
Q4 2014 | $5,595,000 | +47.1% | 99,964 | +19.2% | 0.00% | +50.0% |
Q3 2014 | $3,803,000 | +15.1% | 83,883 | +5.0% | 0.00% | 0.0% |
Q2 2014 | $3,305,000 | -17.7% | 79,851 | +36.7% | 0.00% | -33.3% |
Q1 2014 | $4,017,000 | +20.6% | 58,414 | +5.6% | 0.00% | +50.0% |
Q4 2013 | $3,331,000 | -36.8% | 55,303 | -36.2% | 0.00% | -50.0% |
Q3 2013 | $5,271,000 | – | 86,717 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |